Personalizing Polymyxin B dosing using an adaptive feedback control algorithm

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 7, 2018, Pages

  Lakota, Elizabeth A ^a,b   Landersdorfer, Cornelia B ^c   Nation, Roger L ^c   Li, Jian ^c   Kaye, Keith S ^d   Rao, Gauri G ^a,e   Forrest, Alan ^a,e  

^a UNIVERSITY AT BUFFALO   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Adaptive feedback control; Multidrug resistant organisms; Nephrotoxicity; Polymyxins

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG THERAPEUTIC INDEX; FEEDBACK SYSTEM; HUMAN; MEDLINE; META ANALYSIS; MONTE CARLO METHOD; NEPHROTOXICITY; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; GRAM NEGATIVE INFECTION; INJURY; KIDNEY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ALGORITHMS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B;

EID: 85049019826     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00483-18     Document Type: Article

References (41)

1. Ryan KJ, Schainuck LI, Hickman RO, Striker GE. 1969. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 207:2099–2101.
2. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. 1970. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72:857–868.
3. Vozeh S, Steimer JL. 1985. Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application. Clin Pharmacokinet 10:457–476.
4. D’Argenio DZ, Khakmahd K. 1983. Adaptive control of theophylline therapy: importance of blood sampling times. J Pharmacokinet Biop-harm 11:547–559. https://doi.org/10.1007/BF01062211.
5. Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR. 2017. Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci 10:443–454. https://doi.org/10.1111/cts.12490.
6. Velkov T, Thompson PE, Nation RL, Li J. 2010. Structure-activity relationships of polymyxin antibiotics. J Med Chem 53:1898–1916. https://doi.org/10.1021/jm900999h.
7. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88–94. https://doi.org/10.1093/cid/ciu213.
8. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300 –1303. https://doi.org/10.1093/cid/cit453.
9. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43: 349–352. https://doi.org/10.1016/j.ijantimicag.2013.12.002.
10. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:2740–2746. https://doi.org/10.1128/AAC.02476-13.
11. Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP. 2016. Multi-center prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60: 2443–2449. https://doi.org/10.1128/AAC.02634-15.
12. Zavascki AP, Nation RL. 2017. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother 61:e02319-16. https://doi.org/10.1128/AAC.02319-16.
13. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3624 –3630. https://doi.org/10.1128/AAC.49.9.3624-3630.2005.
14. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54:3783–3789. https://doi.org/10.1128/AAC.00903-09.
15. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70:3291–3297. https://doi.org/10.1093/jac/dkv267.
16. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380. https://doi.org/10.1186/1471-2334-13-380.
17. Forrest A, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Li J, Silveira FP, Nation RL. 2017. Pharmacokinetic/ toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients. Antimicrob Agents Chemother 61:e01367-17. https://doi.org/10.1128/AAC.01367-17.
18. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:879–884. https://doi.org/10.1093/cid/cir611.
19. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231–2237. https://doi.org/10.1093/jac/dkq285.
20. Pastewski AA, Caruso P, Parris AR, Dizon R, Kopec R, Sharma S, Mayer S, Ghitan M, Chapnick EK. 2008. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother 42:1177–1187. https://doi.org/10.1345/aph.1K346.
21. Teng CB, Koh PT, Lye DC, Ang BS. 2008. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 31:80–82. https://doi.org/10.1016/j.ijantimicag.2007.08.004.
22. Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL. 2018. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother 73:462–468. https://doi.org/10.1093/jac/dkx409.
23. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524–531. https://doi.org/10.1093/cid/cit334.
24. Gales AC, Jones RN, Sader HS. 2006. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance pro-gramme (2001-2004). Clin Microbiol Infect 12:315–321. https://doi.org/10.1111/j.1469-0691.2005.01351.x.
25. EUCAST. 2017. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf.
26. Justo JA, Bosso JA. 2015. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 35:28–33. https://doi.org/10.1002/phar.1493.
27. Liang SY, Kumar A. 2015. Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. Curr Infect Dis Rep 17:493. https://doi.org/10.1007/s11908-015-0493-6.
28. Ahn JE, French JL. 2010. Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37:179–201. https://doi.org/10.1007/s10928-010-9152-6.
29. Kellum JA, Bellomo R, Ronco C. 2007. The concept of acute kidney injury and the RIFLE criteria. Contrib Nephrol 156:10–16. https://doi.org/10.1159/000102010.
30. D’Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
31. R Development Core Team. 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
32. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multire-sistant gram-negative bacteria. Antimicrob Agents Chemother 47: 2659–2662. https://doi.org/10.1128/AAC.47.8.2659-2662.2003.
33. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. 2006. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 40:1939–1945. https://doi.org/10.1345/aph.1H353.
34. Ramasubban S, Majumdar A, Das PS. 2008. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J Crit Care Med 12:153–157. https://doi.org/10.4103/0972-5229.45074.
35. Mendes CA, Cordeiro JA, Burdmann EA. 2009. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother 43:1948–1955. https://doi.org/10.1345/aph.1M277.
36. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. 2009. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65:431–434. https://doi.org/10.1016/j.diagmicrobio.2009.07.018.
37. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. 2011. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 66:175–179. https://doi.org/10.1093/jac/dkq390.
38. Esaian D, Dubrovskaya Y, Phillips M, Papadopoulos J. 2012. Effectiveness and tolerability of a polymyxin B dosing protocol. Ann Pharmacother 46:455–456. https://doi.org/10.1345/aph.1Q294.
39. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. 2012. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65:80–87. https://doi.org/10.1016/j.jinf.2012.01.015.
40. Nandha R, Sekhri K, Mandal AK. 2013. To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B. Indian J Crit Care Med 17: 283–287https://doi.org/10.4103/0972-5229.120319.
41. Crass RL, Rutter WC, Burgess DR, Martin CA, Burgess DS. 2017. Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin. Antimicrob Agents Chemother 61:e02329-16https:// doi.org/10.1128/AAC.02329-16.